Academic Editor: Chen Chen
Diabetes Mellitus is a highly prevalent disease in Mexico and in the world, among whose complications is diabetic neuropathy. DN is a group of disorders that present signs and/or symptoms of peripheral nerve dysfunction and have different clinical manifestations in both peripheral neuropathy and autonomic neuropathy. As a part of the mechanisms by which DN develops, oxidative stress and inflammation have been described. Cocoa is a plant origin product which includes around 300 components and through different studies, it has been suggested that cocoa has different mechanisms of action through which exerts its beneficial effects on health. It has been proposed that cocoa has hypoglycemic, lipid-lowering, antioxidant and anti-inflammatory effects, and thus, potentially have a beneficial direct or indirect effect on diabetic neuropathy. Specially in preclinical studies, the anti-inflammatory and anti-nociceptive effect of cocoa has been evaluated through different mechanisms of action. However, most of the studies presented concerning this complication, are in vitro or preclinical studies, so there is still a great area of opportunity regarding the use of cocoa on diabetic neuropathy.
Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by
persistent hyperglycemia and occurs due to dysfunction in insulin secretion,
resistance, or both [1]. Insulin resistance (IR) is the inability of the hormone
to stimulate peripheral glucose uptake, as well as other signaling pathways in
different tissues [2, 3], and it develops as a consequence of the accumulation of
fat in the muscle and organs such as the liver and pancreas. In the latter organ,
dysfunction of the pancreatic
Type 2 diabetes (T2D) refers to the relative deficiency of insulin secondary to a progressive dysfunction of its secretion, frequently with a previous period of IR. This type of diabetes accounts for 90–95% of all cases [5]. According to the International Diabetes Federation, in 2019, it was estimated that the global prevalence of DM in adults aged 20 to 79 years is 9.3%, and for the North American and Caribbean region, it is 13.3% [1]. In Mexico, according to the National Health and Nutrition Survey (ENSANUT) of 2018, it was reported that 10.3% of adults over 20 years of age have a T2D diagnosis, which corresponds to 8.6 million people [6].
When a metabolic lack of control related to hyperglycemia persists, macro and microvascular complications can develop. The former involves cardiovascular disease, eg of the large blood vessels, while the latter include retinopathy, nephropathy and diabetic neuropathy (DN) and are caused by pathological changes of the capillaries, which participate in transport of oxygen and nutrients to the different body systems, including the nervous system [1, 7]. In studies in Mexico, it has been reported that, on average, 50% of patients living with DM develop DN, and it is possible to observe it from 5 years after diagnosis of the disease [8, 9].
DN is a group of disorders that present signs and/or symptoms of peripheral nerve dysfunction and have different clinical manifestations in both peripheral neuropathy and autonomic neuropathy [7, 10].
As a part of the mechanisms by which DN develops, oxidative stress has been
described, which occurs as a consequence of an imbalance between the production
of reactive oxygen species (ROS) and endogenous antioxidant systems [11] and the
state of inflammation [12]. Hyperglycemia can induce oxidative stress by causing
the accumulation of glucose and glycolysis intermediates, and with it, altering
the electron transport chain, decreasing the production of H
Additionally, hyperglycemia can stimulate macrophages to secrete proinflammatory
cytokines such as tumor necrosis factor alpha (TNF-
To date, there is no specific dietary treatment for DN, but the goal is glycemic control, therefore, the American Diabetes Association and the Joslin Diabetes Center, propose weight loss as management for T2D, in case of overweight or obesity and the following macronutrient distribution [14, 15].
The carbohydrate recommendation is 40–45% of the total energy value (TEV), including vegetables, fruits, whole grains and dairy products, as well as 20–35 g of fiber per day; 30–40% of the TEV of lipids, giving greater relevance to monounsaturated and polyunsaturated fatty acids and limiting saturated fatty acids to less than 10%; protein of 1 to 1.5 g/kg adjusted weight/day, which corresponds to 15–30% of the TEV and less than 2300 mg/day of sodium, that is, 1 teaspoon of salt per day [14, 15].
Also, eating patterns such as the Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH) diet, vegetarian diets or low carbohydrate diets could be used to achieve greater metabolic control [14, 15].
Cocoa (Theobroma cacao) is a tree that has been cultivated in several countries of America, including Mexico, and from which one of the most consumed products in the world is derived, chocolate [16].
Cocoa refers to the fruit that has not undergone any transformation, while cocoa powder is the powder that comes from the fruit manufacture, and it is used more frequently in cooking and in daily consumption. On the other hand, chocolate is the product that results after the cleaning, roasting, shelling, grinding and refining cocoa and the addition of milk, sugar or other ingredients [16].
Cocoa has been used, since the Mayas in South America, and it is thought that Christopher Columbus was the first European to meet cocoa beans, which were used as a form of currency [16]. Cocoa not only had an economic use but has also been used for its healing properties, either as a remedy or as a vehicle to deliver other medicines of Mesoamerica [17].
There are reports from European travelers and the Badianus Manuscript, dated between 1536 to 1671, which informed that beverages were prepared with cocoa for therapeutic purposes and the use of cocoa derivatives as nutrients or remedies [18].
Cocoa includes around 300 components, as shown in Fig. 1, among which are cocoa butter, made up of oleic, palmitic and stearic fatty acids; minerals like magnesium, potassium, iron and zinc; methylxanthines such as theobromine and caffeine; compounds like tyramine, tryptophan, and serotonin; and polyphenols, including flavanols such as catechin and epicatechin [19, 20].
Fig. 1.Cocoa bioactive compounds.
Methylxanthines are alkaloids present in cocoa. Theobromine (3,7-dihydro-3,7-dimethyl-1H-purine, 2,6-dione), is the main alkaloid in cocoa trees, seeds and shells. The second most important methylxanthine is caffeine, followed by theophylline and theacrine [21].
On the other hand, within polyphenols, cocoa is composed of monomers, oligomers
and polymers of flavanols. The most common monomers are epicatechin (up to 35%
of the polyphenol content), and
It also contains dimers such as procyanidins B2 (PB2) and B1, (–) epicatechin and (+) catechin in greater amounts, and, in lesser amounts, quercetin, quercetin 3-O-glucoside, quercetin 3-O-galactoside, naringenin, luteolin and apigenin [22, 23].
The absorption of the different flavanols that the cocoa bean has, varies depending on the type of compound. In vitro studies have shown that procyanidins are hydrolyzed into oligomers in the stomach due to the effect of pH, while monomers such as catechin and epicatechin remain stable [22, 24].
Once the monomers and oligomers reach the small intestine, they undergo a phase II biotransformation. This process produces o-methylated, o-sulfated and o-glucuronidated metabolites in the intestinal mucosa, which can be absorbed into the bloodstream [22, 24].
Monomers such as catechin and epicatechin have higher absorption rates, ranging from 22 to 55%, while dimers and trimers of procyanidins are absorbed, on average, by 0.5% [22].
Epicatechin appears in plasma in higher concentrations than catechins and Holt et al reported that there is a preference for epicatechin absorption. Similarly, (+) catechin is more bioavailable than (–) catechin [22]. When (–) epicatechin and procyanidin B2 are administered orally, either individually or as components of cocoa powder, the absorption of (–) epicatechin is just as efficient [24].
Procyanidins with a high degree of polymerization cannot be absorbed in the small intestine and reach the colon, where the microbiota microorganisms form phenolic compounds that can be absorbed, reach the liver and undergo a phase II biotransformation [22, 24].
In vivo studies have shown that cocoa metabolites can be observed in the circulation 30–60 min after ingestion and reach their maximum peak concentration in plasma within 2–3 h [25]. Epicatechin reaches its maximum concentration in plasma at 2 h, and 20% of the consumed epicatechin is excreted in urine [26].
A study determined the concentrations of (–) epicatechin and procyanidin B2 after 30 and 120 min of the intake of 0.375 g of cocoa/kg in healthy subjects, with an average contribution of 26.5 g of cocoa, 323 mg of monomers and 256 mg of dimers. It was observed that at both 30 and 120 min, the plasma levels of (–) epicatechin were higher than those of procyanidin B2 [24].
Although the absorption of epicatechin is higher, the concentrations of these flavanols are much higher in the intestine than in peripheral tissues. After the ingestion of cocoa, the concentration of epicatechin and procyanidin B2 in circulation are on average, from 0.010 to 6 mcM, while after de ingestion of 5 g of cocoa powder, with an average content of 6 mg of catechin, 25 mg of epicatechin and 235 mg of procyanidins, the concentrations found in the intestine were 10 mcM of catechin, 43 mcM of epicatechin and 67 mcM of procyanidins. Which may imply a greater requirement to have effects at the peripheral level [22].
One of the proposed methods for the extraction of flavanols such as catechin, epicatechin, and alkaloids such as theobromine, caffeine and theophylline, is by supercritical fluid extraction [27].
This super critical state is achieved when a substance is subjected to temperature and pressure beyond its critical point, that is, you have a critical fluid when the distinctive phases of gases and liquids are no longer recognized. The supercritical fluid cannot liquefy even if the pressure is increased, nor can it vaporize even if the temperature is increased [27].
Another method that can be used to obtain polyphenols and antioxidants from cocoa pod husk, such as epicatechin, caffeine and theobromine, is ultrasound, based on the fundamentals of wave frequency. For this, it can be used an ethanol: water solution as extraction solvent with a ratio 1:1 (v/v) [28, 29, 30].
Through different studies, especially in vitro studies, it has been suggested that cocoa has different mechanisms of action through which it exerts its beneficial effects on health [24].
Flavanols like catechins, have a chemical structure consisting of 2 rings (A and B), joined by 3 carbons that, together with oxygen, form a third heterocyclic ring (C). These flavanols have several hydroxyl groups in their 3 rings, which are associated with antioxidant effects, since they act as electron donors that stabilize free radicals [24].
Also, the degree of polymerization, the number and distribution of hydroxyl groups, influence the type of interaction with cell membranes since flavanols can divide in the hydrophobic part of the membranes or form hydrogen bonds with the polar heads of the membrane of lipids, and when inserted into the lipid bilayer, they can neutralize ROS and radicals that derive from lipid peroxidation [24].
In studies with Jurkat T cells, it has been observed that procyanidins that come from cocoa have interactions with phospholipids that can also be associated with protecting the integrity of cell membranes, since they limit the access of some molecules that require binding to the hydrophobic region to generate negative effects [24, 31].
Speaking about inflammation, one study suggested that one of the mechanisms by which cocoa might decrease inflammation is through the inhibition of cyclooxygenase 2 (COX-2) or prostaglandin-endoperoxide synthase 2 (PTGS-2) [32].
The structure of COX-2 has 2 heme groups that function as prosthetic groups found un the active site of the enzyme. The (+) catechin and (–) epicatechin bind to COX-2 through the heme group, and thus, inhibit the enzyme, reducing inflammation [32].
Also, by reducing ROS, the release of the active nuclear factor kappa B
(NF-
Another direct mechanism that has been proposed is the chelation capacity of metals such as iron and copper, since it has been that, in stated of oxidative stress, there is an alteration in iron homeostasis, which increases its intracellular concentration and promotes ROS production and oxidative protein and DNA damage. This chelation property is a consequence of the presence of a catechol group in ring B and of the hydroxyl groups, since they have a high affinity for metal ions [24, 34].
The consumption of cocoa has been associated with the decrease in blood glucose levels and with the decrease of lipids such as total cholesterol and triglycerides (TG), promoting glucose transporters 4 (GLUT4) translocation in insulin-sensitive tissues through activation of the adenosin-monophosphate activated kinase (AMPK) signaling pathway is part of the mechanism by which hyperglycemia decreases [24]. While the lipid-lowering effect can be reflected by decreasing intestinal absorption of TG, by blocking the interaction between pancreatic lipase and the surface of the emulsified lipid drops. This effect has been attributed both to the peptides in this food and to (–) epicatechin and other oligomers. It may also be due to the decrease in the solubility of intestinal micelles, in turn, decreasing the concentration of cholesterol [24, 35].
The hypoglycemic and lipid-lowering effect are relevant since both alterations
are involved in the pathophysiology of DN. The consumption of catechins has been
associated with a decrease in hyperglycemia and insulin resistance through the
modulation of proinflammatory cytokines such as IL-1
Also, the different cocoa polyphenols have been related to the attenuation of
the postprandial glycemic response and fasting hyperglycemia, improving insulin
sensitivity and secretion. Possible mechanisms proposed are inhibition of
carbohydrate digestion and glucose absorption at the intestinal level,
stimulation of insulin secretion by pancreatic
Studies have suggested that cocoa consumption is associated with a decrease in
transcription and secretion of adhesion molecules such as intercellular adhesion
molecule (ICAM-1) and P-selectin and proinflammatory cytokines such as IL-6 and
TNF-
Monagas et al. [38] evaluated the effects of cocoa consumption on the expression of adhesion molecules and proinflammatory cytokines in subjects at high risk of coronary heart disease, including subjects with diabetes. They found a decrease in ICAM-1 and P-selectin but no difference in other inflammatory markers such as C reactive protein (CRP) and IL-6 [38].
A study which included individuals with obesity and at risk for insulin resistance and evaluated the effect of cocoa beverages with different flavanol doses, found a decrease in IL-6 and CRP concentrations but no difference on ICAM or fibrinogen values [39].
It has been observed in in vitro studies that epicatechin, catechin and
dimeric procyanidins inhibit the activation of NF-
The effect of catechins from various food sources, such as green tea, on diabetes mellitus has been studied, in which it has been found that catechin can inhibit proinflammatory cytokines and activate AMPK, protein kinase B and other signaling pathways that allow an adequate functioning of the mitochondrial respiratory chain [36].
When there is an adequate functioning of the respiratory chain, there is protection to the pancreatic islets, decrease in insulin resistance and intracellular accumulation of glycogen. Catechin also has inhibitory effects on enzymes that degrade glucose [36].
At the neurological level, it has been observed that the consumption of cocoa
and its flavonoids can reduce the risk of neurodegenerative diseases derived from
oxidative stress, such as Alzheimer’s and Parkinson’s disease; reduce depression
due to its tryptophan content and its consequent conversion to serotonin; provide
protective effects against amyloid
In preclinical studies, the anti-inflammatory and anti-nociceptive effect of cocoa has been evaluated through different mechanisms of action, among which are:
Inhibition of the activation of trigeminal neurons and the expression of proteins involved in nociception in the ganglion and spinal cord [40, 41, 42].
Increase in peptides with anti-inflammatory and antinociceptive properties such as protein mitogen activated protein (MAP) kinase phosphatases 1 (MPK-1) [41, 42].
Decrease in the expression of the peptide related to the calcitonin gene (CGRP) in the spinal trigeminal nucleus, same as at the glial cell level, it is capable of increasing cell activation, producing a greater amount of proinflammatory molecules [40, 41, 42].
Decrease in the expression of inducible nitric oxide synthase (iNOS), which increases the production of nitric oxide and acts as a free radical and participated in the initiation and increase of the inflammatory process and pain [41, 43].
Also, proinflammatory cytokines, such as IL-1
In a study carried out with rats with diabetes, Addepalli and Suryavanshi administered 25 and 50 mg/kg of catechin intraperitoneally, and observed that catechin decreases the neuronal damage caused by oxidative stress and improves antioxidant enzymes. In control rats, an increase in oxidative stress was found in the vagus nerve by observing an increase in malondialdehyde (MDA) levels and a decrease in glutathione, catalase and superoxide dismutase, the same effects were reversed in the treatment groups with catechin [44].
Also, in these intervention groups there was a decrease in the proliferation of Schwan cells, lymphocytic infiltration and demyelination of the vagus nerve, probably secondary to the inhibition of the inflammatory cascade and the increase in myoinositol levels, which modulated demyelination [44].
The following is a summary of the reviewed literature (Table 1, Ref. [32, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]). Evidence of the effect of cocoa and its bioactive compounds on T2D, markers of inflammation and oxidative stress and DN is attached.
| Author | Study design | Population | Dose | Duration | Main findings |
| Parsaeyan, et al. 2014 [32] | RCT | 100 subjects with T2D and dyslipidemia. | I: 10 g cocoa powder + 10 g milk powder in 250 mL of water, 2 times/day. | 6 weeks | I: Total cholesterol ↓ 16.57%, LDL ↓ 17.54%, TG ↓ 13.3%, CRP, TNF-α and IL-6 ↓. |
| Age: 40–70 years. | C: 10 g milk powder in 250 mL of water, 2 times/day. | C: MDA ↑ 17.75% | |||
| Jafarirad, et al. 2018 [45] | Parallel | 44 subjects with T2D. | I: Therapeutic lifestyle changes + 30 g of 84% dark chocolate. | 8 weeks | I: FS ↓ 15 |
| RCT | Age: 30–60 years. | C: just therapeutic lifestyle changes. | mg/dL, TG ↓ 33.6 | ||
| Maskarinec, et al. 2019 [46] | Multiethnic cohort | 151,691 subjects. | Asked about the intake of cocoa products (drinks and chocolate bars). | 7.8 |
Incidence of T2D: -Intake |
| Age: 45–75 years. | Classified based on the intake of the products and flavanols. | -Chocolate consumption | |||
| -Consumption of drinks with chocolate | |||||
| *Major effects in women and the Japanese-American population. | |||||
| Munguía, et al. 2015 [47] | RCT | Overweight subjects with 2 of the following: | I: General dietary recommendations + 30 minutes of brisk walking daily and cocoa extract powder with 80 mg of flavonoids in 200 mL of water. | 4 weeks | I: Weight ↓ 3 |
| -Abdominal circumference: |
C: Same dietary recommendations and walking and placebo. | Carbonyl ↓ 16.7 | |||
| -FS: 120–126 mg/dL. | |||||
| -TG: 150–200 mg/dL. | |||||
| -HDL: |
|||||
| -Systolic BP 120–135 mmHg and/or diastolic BP 80–90 mmHg. | |||||
| Age: 20–60 years | |||||
| Ramiro-Puig, et al. 2009 [48] | In vitro | Human neuroblastoma cell line (SH-SY5Y) à used to study oxidative stress-induced cell death. | ROS production: | 30 min at 37 |
Both cocoa extract and (–) epi ↓ ROS production in a dose-dependent manner (up to 60% in non-stimulated cells). |
| Cocoa extract (0.1–30 mcg/mL) or (−) epi (0.3–29 mcg/mL) for 30 min at 37 |
After stimulating cells with H | ||||
| Activation of AMPK: | Apoptotic pathways: | ||||
| Cocoa extract (0.1–1 mcg/mL), (−) epi (0.15–7.3 mcg/mL) or vehicle for 30 min at 37 |
In cells stimulated with H | ||||
| (–) epi ↓ phosphorylation of p38 (only in doses higher than those of cocoa extract), JNK and p-ERK1/2 (70%). | |||||
| Ruzaidi, et al. 2005 [49] | Preclinic | 80 male Wistar rats with streptozotocin-induced diabetes. | Group 1: control rats + normal diet. | 4 weeks | ↓ in glucose levels in rats with DM and normal diet and 1, 2 and 3% cocoa extract. |
| Group 2: control rats + cocoa extract. | In rats with DM + 1 and 3% cocoa extract: ↓ total cholesterol. | ||||
| Group 3: DM + normal diet. | In all rats with DM: ↓ TG. | ||||
| Group 4: DM + cocoa extract. | In rats with DM + 2% cocoa extract: ↑ HDL. | ||||
| *1, 2 and 3% cocoa extract. | In rats with DM + 1% cocoa extract: ↓ LDL. | ||||
| Martín, et al. 2014 [50] | In vitro | INS-1E rat pancreatic cells. | 5, 10 and 20 micromoles of epi. | 20 h prior to the administration of t-BOOH for 2 h. | In cells treated with t-BOOH, epi prevented glutathione depletion and recovered glutathione peroxidase to pre-stress levels. |
| Epi ↓ ROS production. | |||||
| 10–20 mcM of epi recovered the levels of carbonyls similar to the levels of the control group. | |||||
| 20 mcM of epi ↑ basal insulin secretion and under glucose stimulation conditions. | |||||
| Addepalli, Suryavanshi. 2018 [44] | Preclinic | Male Sprague Dawley rats with streptozotocin-induced diabetes. | C1: normal control. | 28 days | I1 and 2: glucose ↓, MDA ↓, glutathione and superoxide dismutase ↑. |
| C2: diabetic rats + 0.5% w/v CMC. | I2: reversed neuronal damage to normal levels and mitigated neuropathic | ||||
| I1: 25 mg/kg of catechins in 0.5% w/v CMC intraperitoneally. | lesions in the vagus nerve. | ||||
| I2: 50 mg/kg of catechins in 0.5% w/v CMC intraperitoneally. | |||||
| Anjaneyulu, Chopra. 2003 [51] | Preclinic | Male albino mice with streptozotocin-induced diabetes. | Group 1: quercetin vehicle. | 4 weeks | 100 mg/kg of quercetin has an antinociceptive effect in control and DM |
| Group 2: quercetin in suspension 50 mg/kg. | mice, being more effective in DM mice. | ||||
| Group 3: quercetin suspension 100 mg/kg. | Naloxone + quercetin completely attenuated the antinociceptive effect of | ||||
| Group 4: naloxone (2 mg/kg) + quercetin (100 mg/kg). | quercetin. | ||||
| Group 5: naloxone | |||||
| Al-Rejaie, et al. 2015 [52] | Preclinic | Male Wistar rats with streptozotocin-induced diabetes. | C: vehicle treated normal rats. | 5 weeks | I2: ↓ TNF-α, IL-1β, IL-6 in the sciatic nerve. |
| C2: vehicle treated diabetic rats. | ↑ glutathione and IGF, and superoxide dismutase and catalase activity. | ||||
| I1: Naringenin 25 mg/kg orally. | |||||
| I2: 50 mg/kg orally. | |||||
| Ding, et al. 2014 [53] | Preclinic | 50 Sprague Dawley rats with streptozotocin-induced diabetes. | Group 1: normal + vehicle | 24 total weeks (16 weeks | Group 3: ↓ the NCV, compared to group 1, while in group 4, ↑ the NCV. |
| Group 2: normal + 250 mg/kg GSP | after induction of T2D) | In group 3: sciatic nerve damage, dilated mitochondria and endoplasmic reticulum in Schwann cells. | |||
| Group 3: T2D + vehicle | In group 4: moderate ↑ of normal mitochondria and endoplasmic reticulum. | ||||
| Group 4: T2D + GSP | |||||
| *By gastric tube | |||||
| In vitro | Schwann cells cultured from 10 healthy Sprague Dawley rats and 20 rats with T2D. | Pretreatment with a combination of catechin and epi at doses of 5, 10 and 20 mcM/L and induction of stress to endoplasmic reticulum with 5 mcg/mL of tunicamycin. | 48 h | The increase of free cytoplasmic Ca2+ was blocked. | |
| Pretreatment with 5 and 10 mcM/L ↓ stress on the endoplasmic reticulum. | |||||
| BP, Blood Pressure; C, Control; CMC, Carboxymethylcellulose; CRP, C-Reactive
Protein; DM: Diabetes Mellitus; epi, Epicatechin; FS, Fasting glucose; GSP, Grape
Seed Proanthocyanidins; HDL, High-Density Lipoprotein; HR, Hazard Ratio; I,
Intervention; IGF, Insulin Growth Factor; IL-6, Interleukin 6; JNK, c-Jun
n-terminal Kinase; LDL, Low-Density Lipoprotein; MDA, Malondialdehyde; NCV, Nerve
conduction velocity; RCT, Randomized Controlled Trial; ROS, Reactive Oxygen
Species; T2D, Type 2 Diabetes; t-BOOH, tert-butylhydroperoxide; TG,
Triglycerides: TNF- | |||||
After reviewing the literature, it is possible to observe a series of limitations and the most important is that the studies described above regarding DN, are mainly in vitro and preclinical studies. This implies that clinical studies are required to specifically evaluate the effect of cocoa on DN, and thus, to be able to determine the necessary doses, supplementation time and the specific bioactive compound or set of compounds that generate the desired effect.
In addition to the type of studies, the doses that were used and the compounds studied are different, which makes it even more difficult to provide recommendations to the population. Even the studies that used the same compounds or products, used different doses.
For example, Munguía et al. [47] in a clinical study, report the use of cocoa extract powder with 80 mg of flavonoids, while in preclinical, Ruzaidi et al. [49] report the use of 1, 2 and 3% cocoa extract, with a total phenolic content of 285.6 mg/g.
Most of the studies that were reviewed that investigated cocoa extract or its main flavanol, (–) epicatechin, are directly on the pathology of T2D, in which favorable results have been found, finding an improvement in glycemic and lipidic profile, contributing to cardiometabolic control. However, specifically for the management of DN, there is not much evidence yet and the few studies that have been found, use other compounds isolated such as quercetin, proanthocyanidins and naringenin.
Speaking of cocoa, in the studies that were reviewed for the present, cocoa is included in different presentations, either in chocolate, in a beverage, the cocoa extract, or its bioactive components in isolation, so it is difficult to make recommendations or conclusions based on such studies, since its presentation could increase or decrease the bioavailability of bioactive compounds, and furthermore, it is not possible to know if the beneficial effect is due to all of them or to a special compound.
In case a well-defined and strong effect is observed with a specific compound, it would be preferable to consume the isolated bioactive compound, since these (for example, quercetin and naringenin), are found in small amounts in cocoa.
In order to determine if there is strong evidence that allows the recommendation of cocoa or any of its bioactive compounds, it is necessary to define the objective.
Evidence shows that cocoa contributes to an improvement in the cardiometabolic profile, by reducing blood glucose, HbA1c, lipid profile, inflammation markers and oxidative stress markers. The alteration of these parameters contributes to the development of complications of DM, including DN, which could indirectly delay the progression of this microvascular complication.
Published reviews suggest that, due to the characteristics of the main bioactive compounds in cocoa, they could exert beneficial effects on DN. However, no preclinical or clinical studies have yet been conducted to support the use of cocoa or any of its bioactive compounds to prevent, treat, or improve this complication.
Taking into account the clinical studies reviewed, it is not possible to make recommendations for subjects with DN, but it is feasible to recommend the consumption of chocolate or cocoa powder to individuals with T2D and dyslipidemias since beneficial effects are observed in proinflammatory cytokines, MDA, blood lipids, glycemia and HbA1c, and thus, having a probable indirect effect on neuropathy, using doses that are available on the market and easily consumable. In addition, chocolate is a food accessible to the population and that is generally liked, so it would be easily accepted within the eating habits of different age groups.
These studies evaluated 20 g of cocoa powder a day with milk and 30 g of chocolate with 84% cocoa, quantities that are practical and can be implemented in the diet, however, one of the limitations that may arise when putting it into practice, is that in Mexico there is a great variety of chocolates such as milk chocolate and dark chocolate, each with a different contribution of polyphenols, fats and sugars, with which the same answer would not be seen, and, probably, it’s abuse, could be associated with adverse health effects.
AMPK, Adenosin-monophosphate activated kinase; BP, Blood pressure; C, Control;
CMC, Carboxymethylcellulose; CGRP, Peptide related to the calcitonin gene; COX-2,
Cyclooxygenase 2; CRP, C-Reactive Protein; DASH, Dietary approaches to stop
hypertension; DM, Diabetes Mellitus; DN, Diabetic Neuropathy; ENSANUT, National
Health and Nutrition Survey; Epi, Epicatechin; FS, Fasting glucose; GLUT 4,
Glucose transporters 4; GSP, Grape Seed Proanthocyanidins; HbA1c, Glycated
Hemoglobin A 1 c; HDL, High-Density Lipoprotein; HR, Hazard Ratio; I,
Intervention; ICAM-1, Intercellular adhesion molecule 1; IGF, Insulin Growth
Factor; IL, Interleukin; iNOS, Inducible nitric oxide synthase; IR, Insulin
Resistance; JNK, c-Jun n-terminal Kinase; LDL, Low-Density Lipoprotein; MAP,
Mitogen Activated Protein; MDA, Malondialdehyde; NCV, Nerve conduction velocity;
NF-
RKA collected information and wrote first draft, together with corrections. NVM and GMRC conceived draft and first analyzed such. GGS reviewed, edited, formatted, and chaired the present manuscript.
Not applicable.
Not applicable.
This research received no external funding.
The authors declare no conflict of interest.